Stockreport

AstraZeneca's Enhertu granted approval for HER-2 positive tumor-agnostic indications [Seeking Alpha]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF The acclerated approval of the sBLA for Enhertu, which is marketed along with Daiichi Sankyo ( OTCPK:DSKYF ), means that the antibody drug conjugate is the first to [Read more]